This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A decade ago, neuro-oncologists began asking important questions about the optimal management of patients with low-grade gliomas of the cerebral hemispheres.1 Should all patients be exposed to the risks of surgery, simply for diagnosis? Does radiotherapy prolong tumor control and patient survival? Is early radiotherapy preferable to delayed treatment? Will better tumor control by radiation be negated by cognitive impairment or other toxicities? Is high-dose radiotherapy more effective than lower dose treatment? Is there a role for chemotherapy in the treatment of low-grade glioma? In this issue of Neurology, Olson et al.2 address many of these important questions as they pertain to patients with oligodendrogliomas and oligoastrocytomas, two subtypes of hemispheric low-grade glioma with similar clinical features and molecular origins.
Their analysis shows that patients with oligodendrogliomas and oligoastrocytomas have remarkably favorable prognoses. The median progression-free survival time in this series was 5 years, and the median overall survival time was 16.3 years. These good outcomes, among the best “on-record,” attest to the slow growth of oligodendrogliomas and mixed gliomas and to earlier diagnosis in the era of modern neuroimaging. Since the introduction of CT and …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
